Home » IVT RNA Production Services » Catalog IVT mRNA, circRNA, saRNA, LNP products » eSpCas9 mRNA(Cap1, m1Ψ)

eSpCas9 mRNA(Cap1, m1Ψ)

RP-A00018
$300.00

Ask us a question
Description

The eSpCas9 mRNA expresses enhanced-specificity SpCas9 protein, with sequence originally from Slaymaker et al., Science (2015 Dec 1). eSpCas9 significantly reduces off-target effects (by more than 10-fold), while maintaining high on-target genome editing efficiency.  
 
This mRNA features: 
- A Cap 1 structure with high capping efficiency 
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response 
- GenScript’s patented UTR to enhance translation 
- A 100A poly(A) tail to mimic natural mature mRNA 
 
This construct offers high-precision genome editing with minimized off-target activity, making it ideal for CRISPR validation, therapeutic research, and functional genomics studies.
Properties
Form Liquid
Concentration 1mg/mL
Full mRNA length 4479nt
Full mRNA Molecular Weight 1457890
Storage Store at -20°C for short term (<3 months), store at -80°C for long term.
Storage buffer 1mM Sodium citrate, pH6.5

Quality Control Specifications
Appearance Clear and free of foreign particles
RNA Length Expected size band detected
RNA Content Target ± 5%
Integrity ≥ 75%
OD260/OD280 1.70 ~ 2.30
Capping Efficiency ≥ 90%
Endotoxin < 10 EU/mg
pH Target ± 0.5

Applications
Transfect a total of 0.5-1.5 µg of eSpCas9 mRNA and sgRNA per well (recommended molar ratio 1:10), using a transfection reagent, electroporation, or LNP encapsulation in a 24-well plate (~2 × 10⁵ cells/well). Assess genome editing efficiency 48-72 hours post-transfection via sequencing and ICE analysis.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.